Comparison · NCT02423408-4aab1cf6
TNX-201 vs Placebo: Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TNX-201 vs Placebo: Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period. Trial comparisons, record NCT02423408-4aab1cf6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02423408-4aab1cf6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.213 | 0.136 | 0.319 | wilson | |
| Risk in group 2 | 0.208 | 0.131 | 0.316 | wilson | |
| Risk difference, group 1 minus group 2 | 0.005 | -0.127 | 0.136 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.548 | 1.91 | log | |
| Odds ratio, group 1 over group 2 | 1.03 | 0.466 | 2.28 | log | |
| Number needed to treat, for one more participant with the outcome on TNX-201 than on Placebo | 200 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TNX-201 | 4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs~TNX-201: TNX-201 capsule | 16 | 75 | OG000 |
| Group 2 | Placebo | 4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs~Placebo: Placebo capsule | 15 | 72 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period
- Description
- Time frame
- 24-hour post-dose period
- Population
8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
- NCT number
- NCT02423408
- Phases
- PHASE2
- Conditions
- Tension-Type Headache
- Interventions
- TNX-201, Placebo
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Results first posted
- 2017-02-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02423408?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02423408-4aab1cf6